<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Brainsway Ltd.

    Brainsway Ltd.

    BrainsWay is an industry leader in the field of transcranial magnetic stimulation ...

    BrainsWay is an industry leader in the field of...

    Filing Type:    PU
    Connector LLC

    Connector LLC

    Connector LLC is a corporation that creates highly cost-effective platforms for se...

    Connector LLC is a corporation that creates hig...

    Amount Raised:    $100.00
    Fundraising Status:    EC
    Filing Type:    CF
    Akebia Therapeutics, Inc.

    Akebia Therapeutics, Inc.

    We are a fully integrated biopharmaceutical company focused on the development and...

    We are a fully integrated biopharmaceutical com...

    Filing Type:    PU
    Akers Biosciences Inc.

    Akers Biosciences Inc.

    Akers Biosciences, Inc. (aka Akers Bio) was founded in 1989, with the objective of...

    Akers Biosciences, Inc. (aka Akers Bio) was fou...

    Filing Type:    PU
    BioSculpture Technology, Inc

    BioSculpture Technology, Inc

    BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device man...

    BioSculpture Technology, Inc. (“BST”) is a ...

    Filing Type:    RA
    Amgen Inc.

    Amgen Inc.

    Amgen is committed to unlocking the potential of biology for patients suffering fr...

    Amgen is committed to unlocking the potential o...

    Filing Type:    PU
    Cue Biopharma, Inc.

    Cue Biopharma, Inc.

    Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...

    Cue Biopharma is an innovative clinical stage i...

    Filing Type:    PU
    Inovio Pharmaceuticals, Inc.

    Inovio Pharmaceuticals, Inc.

    Inovio is bringing IMMUNO-INGENUITY™ to life and is reshaping the future of trea...

    Inovio is bringing IMMUNO-INGENUITY™ to life ...

    Filing Type:    PU
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    GlycoMimetics, Inc.

    GlycoMimetics, Inc.

    At GlycoMimetics, we are committed to helping to make a difference in the lives of...

    At GlycoMimetics, we are committed to helping t...

    Filing Type:    PU
    TCR2 Therapeutics Inc.

    TCR2 Therapeutics Inc.

    TCR² is an innovative immunotherapy company developing the next generation of T c...

    TCR² is an innovative immunotherapy company de...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.